Smoking Addiction - Pipeline Review, H1 2016

Description: Smoking Addiction - Pipeline Review, H1 2016

Summary

‘Smoking Addiction - Pipeline Review, H1 2016’, provides an overview of the Smoking Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Smoking Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Smoking Addiction
- The report reviews pipeline therapeutics for Smoking Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Smoking Addiction therapeutics and enlists all their major and minor projects
- The report assesses Smoking Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Smoking Addiction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Smoking Addiction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Smoking Addiction pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Smoking Addiction Overview
Therapeutics Development
Pipeline Products for Smoking Addiction - Overview
Pipeline Products for Smoking Addiction - Comparative Analysis
Smoking Addiction - Therapeutics under Development by Companies
Smoking Addiction - Therapeutics under Investigation by Universities/Institutes
Smoking Addiction - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Smoking Addiction - Products under Development by Companies
Smoking Addiction - Products under Investigation by Universities/Institutes
Smoking Addiction - Companies Involved in Therapeutics Development
Aradigm Corporation
Arena Pharmaceuticals, Inc.
Astraea Therapeutics, LLC
Bioprojet SCR
Cerecor Inc.
CoMentis, Inc.
Embera NeuroTherapeutics, Inc.
Euthymics Bioscience, Inc.
Invion Limited
Johnson & Johnson
Marinus Pharmaceuticals, Inc.
NAL Pharmaceuticals Ltd.
Pfizer Inc.
Selecta Biosciences, Inc.
Zynerba Pharmaceuticals, Inc.
Smoking Addiction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(metyrapone + oxazepam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amitifadine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anatabine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-1.4979 - Drug Profile
Product Description
Mechanism Of Action
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Product Description</th>
<th>Mechanism Of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERC-501</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ganaxolone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>JNJ-39393406</td>
<td></td>
<td></td>
</tr>
<tr>
<td>lorcanostatine hydrochloride</td>
<td></td>
<td></td>
</tr>
<tr>
<td>nadolol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NFL-101</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIC7-DT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
R&D Progress

nicotine bitartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Nicotine Vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

PF-05402536 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

PF-06413367 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

SEL-070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Small Molecule for Smoking Cessation and Appetite Suppression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
Product Description
Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNA3 and CHRNA4 for Smoking Cessation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNA2 and CHRNA4 for Smoking Cessation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URB-694 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Smoking Addiction - Dormant Projects

Smoking Addiction - Discontinued Products

Smoking Addiction - Product Development Milestones

Featured News & Press Releases

Apr 11, 2016: Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Drug Abuse (NIDA) at the National Institutes of Health

Feb 02, 2016: Cerecor Announces Initiation of Phase 2 Clinical Trial With CERC-501 for Smoking Cessation

Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis

Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation

Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation

Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation

Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation

Nov 04, 2014: Lorcaserin Meets Primary Endpoint And Confirms Proof-Of-Concept As Potential Aid For Smoking Cessation In Investigational Phase II Clinical Study

Nov 03, 2014: Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation

Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform

May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ
(lorcaserin HCl) CIV by 50%

Jan 29, 2014: FDA clears path for “Smoking Cessation” clinical trial of INV102 (nadolol)

Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial

Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL

Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Smoking Addiction, H1 2016

Number of Products under Development for Smoking Addiction - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Smoking Addiction - Pipeline by Aradigm Corporation, H1 2016

Smoking Addiction - Pipeline by Arena Pharmaceuticals, Inc., H1 2016

Smoking Addiction - Pipeline by Astraea Therapeutics, LLC, H1 2016

Smoking Addiction - Pipeline by Bioprojet SCR, H1 2016

Smoking Addiction - Pipeline by Cerecor Inc., H1 2016

Smoking Addiction - Pipeline by CoMentis, Inc., H1 2016

Smoking Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H1 2016

Smoking Addiction - Pipeline by Euthymics Bioscience, Inc., H1 2016

Smoking Addiction - Pipeline by Invion Limited, H1 2016
Ordering:  

Order Online - [http://www.researchandmarkets.com/reports/3775394/](http://www.researchandmarkets.com/reports/3775394/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Smoking Addiction - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3775394/
Office Code: SCH3AUOH

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>[ ]</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>[ ]</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>[ ]</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World